Abstract: Disclosed herein relates to the biological activities and preparation of 5-(2-(4-(4-fluoro-2-methyl-1H-indol-5-yloxy)-6-methoxyquinolin-7-yloxy)ethyl)-5-azaspiro[2.4]-heptan-7-ol (Compound A) stable crystalline form (Compound A-Xln); its tablet (Compound A-Xln tablet); its phosphoric acid salt (Compound A-P) and phosphoric acid salt stable crystalline form (Compound A-P-Xln); as well as its enantiomers (Compound R-A, Compound S-A). Furthermore, their anti-cancer activities, stabilities, chirality, dissolutions and treatment indications have also been investigated.

Abstract: The present invention relates to a chemo combination therapy regimen to treat cancer. More specifically, the present invention relates to a novel chemo combination therapy regimen which relates to the combination of compound AL3818 (anlotinib, catequentinib) or its pharmaceutically acceptable salts with standard platinum-based and other chemotherapy agents or immunotherapy agents. The combination of these agents should be able to provide higher efficacy than employing any agent individually.